利奈唑胺方案治疗耐多药结核的系统综述:剂量与PK/PD依据
该系统综述检索利奈唑胺药代动力学/药效学文献,纳入8项研究,发现其PK变异性显著,疗效由AUC/MIC驱动,日剂量600 mg在疗效与毒性间较平衡,建议结合MIC监测与治疗药物监测实现个体化用药。
要点
- 利奈唑胺疗效由AUC/MIC驱动,需联合有效背景药物。
- 日剂量600 mg在疗效与毒性之间较为平衡。
- 利奈唑胺治疗窗窄,可考虑监测MIC与治疗药物监测。
核心结论
- 利奈唑胺疗效似乎由AUC/MIC驱动,日剂量600 mg在疗效与毒性间较平衡。
- 文献对日剂量600 mg的最佳给药方式尚无定论。
- 利奈唑胺治疗窗很窄,个体化用药可能获益。
研究设计与样本
- 系统检索药代动力学/药效学文献,最终纳入8项符合标准的研究。
主要发现
- 纳入研究中观察到显著的药代动力学变异性。
- 利奈唑胺疗效似乎由AUC/MIC驱动。
- 文献对日剂量600 mg的优选给药方式尚无定论。
关键数值与推荐
- 为防止耐药发生,在联合药物达到相关暴露时需AUC/MIC比值达100。
- 日剂量600 mg似乎可在疗效与毒性之间取得平衡。
临床怎么用
- 利奈唑胺治疗可考虑测量实际MIC值并结合治疗药物监测实现个体化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Linezolid has been successfully used for treatment of multidrug-resistant tuberculosis (MDR-TB). However, dose- and duration-related toxicity limit its use. Here, our aim was to search relevant pharmacokinetics (PK)/pharmacodynamics (PD) literature to identify the effective PK/PD index and to define the optimal daily dose and dosing frequency of linezolid in MDR-TB regimens. The systematic search resulted in 8 studies that met inclusion criteria. A significant PK variability was observed. Efficacy of linezolid seems to be driven by area under the concentration-time curve (AUC)/minimum inhibitory concentration (MIC). Literature is inconclusive about the preferred administration of a daily dose of 600 mg. To prevent development of drug resistance, an AUC/MIC ratio of 100 in the presence of a companion drug at relevant exposure is required. A daily dose of 600 mg seems appropriate to balance between efficacy and toxicity. Being a drug with a very narrow therapeutic window, linezolid treatment may benefit from a more personalized approach, that is, measuring actual MIC values and therapeutic drug monitoring.
引用
- Bolhuis MS, Akkerman OW, Sturkenboom MGG, et al. Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. Clin Infect Dis. 2018. PMID: 30496467. doi:10.1093/cid/ciy625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。